How to switch from kratom to Suboxone: the wait window explained
Switching from kratom or concentrated 7-OH to buprenorphine (Suboxone) is a straightforward process when it is done correctly, and timing is the detail that makes the difference. Start too early and you risk precipitated withdrawal, a sudden and severe worsening of symptoms. Wait until the window opens, and the first dose typically brings significant relief within hours.
The fundamental principle: you do not start buprenorphine while kratom or 7-OH is still active in your system. You wait until withdrawal has clearly set in, your prescriber assesses your symptom level, and then the first dose is given.
This article explains the mechanism, the timing, and what the process looks like. The dose itself is determined and adjusted by your prescriber, not by how much kratom you were using.
At a glance: switching from kratom to Suboxone
Key Takeaways
- Timing is everything. Buprenorphine is started only after you are already in mild-to-moderate withdrawal, which for most kratom and 7-OH users means about 12 to 24 hours after the last dose.
- Starting too soon causes precipitated withdrawal. Buprenorphine pushes kratom alkaloids off opioid receptors and only partially activates them, which can trigger a sharp, sudden worsening of symptoms if opioid activity is still present.
- Your prescriber determines the dose. There is no formula connecting how much kratom you used to your stabilizing buprenorphine dose. The dose is set by how your symptoms respond.
- Honest reporting of your last use protects you. Under-reporting when you last used is the main factor that creates precipitated withdrawal risk.
- This is a clinician-supervised process, but it is accessible. Telehealth providers can guide induction in most states, often the same day you reach out.
Why you have to wait: precipitated withdrawal
Buprenorphine is a partial agonist at mu-opioid receptors with very high binding affinity. That high affinity means it binds tightly to opioid receptors and displaces other opioids that are already there, including kratom alkaloids and 7-OH. Because buprenorphine only partially activates the receptor, when it displaces a fuller opioid effect, the net result is a sudden drop in opioid receptor activity.
If that drop happens while significant kratom or 7-OH is still bound to your receptors, the result is precipitated withdrawal: an abrupt, rapid onset of symptoms significantly worse than the withdrawal you were already experiencing. This can include severe vomiting, diarrhea, intense shaking, profuse sweating, and significant anxiety, arriving within minutes of the first dose.
Precipitated withdrawal is not dangerous in the way alcohol or benzodiazepine withdrawal can be, but it is extremely unpleasant and can make people reluctant to try again, which delays getting help. The wait window exists specifically to prevent it.
The kratom-specific nuance: precipitated withdrawal may be somewhat less dramatic with kratom than with full agonist opioids, because kratom alkaloids are partial agonists themselves and do not produce the same degree of receptor occupancy as heroin or oxycodone. However, concentrated 7-OH products activate receptors with substantially more potency than leaf, and the risk is real enough that careful timing remains important regardless of what product was used.
The wait window: how long and how you know
The clock starts at your last dose
The wait is measured from your last use of kratom or 7-OH, not from when you decided to stop. This is why honesty about your last dose matters: the most common factor that leads to precipitated withdrawal is telling a provider you used 18 hours ago when you actually used 8 hours ago. Approximate is fine; the direction of error matters. If anything, err toward reporting use as more recent than you think, not less.
Typical timing for kratom and 7-OH
For concentrated 7-OH and potent extracts, the typical wait before induction is approximately 12 to 24 hours after the last dose. This range is not a fixed rule; it reflects the pharmacokinetics of kratom alkaloids and 7-OH, the product's potency, how frequently you were using, and individual differences in how quickly the compounds clear.
Mitragynine has a half-life of roughly 24 hours in human pharmacokinetic studies. 7-OH itself clears somewhat faster, but at the high concentrations delivered by commercial products, the effective duration of receptor activity can vary. For this reason, some prescribers handling concentrated 7-OH cases use low-dose induction approaches to reduce precipitated withdrawal risk, starting with a smaller initial dose and building from there. Your prescriber will determine the approach appropriate for your situation.
The real signal is your symptoms, not the clock
The clock tells you roughly when the window might open. Your symptoms tell you whether it has. Clinicians use the Clinical Opioid Withdrawal Scale (COWS) to objectively assess withdrawal severity. The COWS evaluates 11 observable signs and symptoms including pulse rate, sweating, restlessness, pupil size, joint aches, runny nose, and cravings, scoring them to produce a total that indicates the severity of withdrawal.
For standard buprenorphine induction, a COWS score typically needs to indicate at least mild-to-moderate withdrawal before the first dose is appropriate. Your prescriber will assess this, either in person or through a telehealth video visit where you report your current symptoms. The first dose follows their assessment, not the clock.
What induction actually looks like
Honest intake comes first
Your prescriber needs an accurate picture of what you have been using. This includes:
- What product you were using (leaf powder, extract, concentrated 7-OH tablet, specific brand and dose if known)
- How often you were using and approximately how much
- When you last used
- What else you have been using alongside (alcohol, benzodiazepines, sleep aids, other substances)
- Any prior experiences with opioid medications or buprenorphine
Commercial concentrated 7-OH products vary widely in actual potency regardless of the label. "I was taking a 300mg Press'd tablet twice a day" gives your provider more clinically useful information than a vague description. Specificity helps; so does honesty about other substances, which significantly changes the risk profile and how induction is managed.
The first dose follows confirmed withdrawal
Once your prescriber assesses your COWS score and confirms you are in the appropriate window, the first dose of buprenorphine is given. For telehealth induction, this usually means you report your symptoms on a video call, the provider assesses you, and you take the medication under direction.
The first dose is not the full stabilizing dose. It is a starting point, calibrated to your symptoms and adjusted based on your response. This is why there is no formula connecting how much kratom you used to your buprenorphine dose. The case series literature shows no reliable correlation between kratom use amount and stabilizing buprenorphine dose. Your dose is set by how you respond to medication, not by what you were using before.
Stabilization takes a few weeks
Most people experience significant symptom relief within the first hours of a correctly timed first dose. Over the following days to weeks, the dose is adjusted as needed. This adjustment period often continues for about two to three weeks as kratom alkaloids fully clear the system and buprenorphine levels stabilize.
It is common to feel that the dose needs adjustment in the first week or two. This is normal and expected, not a sign that the medication is not working. Your prescriber monitors your symptom response and adjusts accordingly. Many people find their symptoms fully stabilize within two to three weeks, though some need a longer period.
Why clinician direction matters
Home induction (taking the first dose without a provider on a call or in person) is practiced in some contexts, but it carries a higher risk of timing errors and precipitated withdrawal, particularly for concentrated 7-OH where the pharmacokinetics are less predictable than for classic heroin or prescription opioids.
The value of a clinician-supervised induction is not bureaucratic. It is that someone is watching your COWS score, can tell you when the window has opened, can calibrate the first dose to your presentation, and can talk you through what is happening in real time. For a process where the difference between the right timing and the wrong timing is the difference between significant relief and a severe symptom surge, that guidance is practically valuable.
Telehealth makes this accessible without requiring a clinic visit. A prescriber can assess your symptoms on a video call and guide you through the first dose from home, in most states, often on the same day you reach out.
Buprenorphine, taken as prescribed, stabilizes the opioid receptors that kratom was activating without producing the highs and lows of active use. Most people describe the first successful dose as the first time in months that they felt stable, rather than managing their day around the next dose.
Frequently Asked Questions
How long do I have to wait after kratom before taking Suboxone?
For most kratom and concentrated 7-OH users, the typical wait is approximately 12 to 24 hours after the last dose. The exact timing varies based on the product, its potency, your frequency of use, and how your body clears the alkaloids. The more reliable signal than the clock is your withdrawal symptoms: your prescriber will assess whether you have reached the right level of withdrawal before directing you to take the first dose.
What is precipitated withdrawal and how do I avoid it?
Precipitated withdrawal is a sudden, rapid worsening of withdrawal symptoms triggered by taking buprenorphine before enough kratom or 7-OH has cleared from your receptors. It happens because buprenorphine displaces the opioid still on your receptors and only partially activates them, causing a sharp net drop in opioid activity. You avoid it by waiting until you are clearly in withdrawal before taking the first dose, and by being honest with your provider about when you last used. Under-reporting your last use is the main cause of precipitated withdrawal during induction.
Does my Suboxone dose depend on how much kratom I was using?
No. Research on buprenorphine for kratom use disorder shows no reliable correlation between how much kratom a person was using and the buprenorphine dose that stabilizes them. Your dose is determined by your symptom response during induction and adjusted from there. This is one of the reasons self-calculating a dose does not work and why prescriber guidance matters.
Can I do induction from home?
Many telehealth providers, including Bicycle Health, guide induction via video call. This means you are at home but a prescriber is assessing your symptoms in real time and directing you on timing and dosage. This is different from completely unsupervised home induction. Telehealth-guided induction is accessible in most states and is often available the same day you reach out.
Does Suboxone work for concentrated 7-OH dependence?
Yes. Buprenorphine acts on the same mu-opioid receptors that 7-OH activates, which is why it stabilizes 7-OH dependence. Published case reports and the 2026 AIM Clinical Cases guidance from Barrett et al. describe buprenorphine as the preferred treatment for significant kratom and 7-OH dependence. For concentrated 7-OH, some prescribers use low-dose induction approaches to reduce precipitated withdrawal risk, given 7-OH's higher receptor potency.
Sources
- Barrett E, Hendy L, Lira MC, et al. What Clinicians Should Know About Kratom and 7-OH Mitragynine. AIM Clinical Cases (Annals of Internal Medicine: Clinical Cases). 2026;5:e251249. doi:10.7326/aimcc.2025.1249. https://www.acpjournals.org/doi/10.7326/aimcc.2025.1249
- Broyan VR, Brar JK, Allgaier Student T, et al. Long-term buprenorphine treatment for kratom use disorder: a case series. Substance Abuse. 2022;43:763-766. doi:10.1080/08897077.2021.2010250. PMID: 35112990.
- Arhin M, Mobley J, Hamad H, Remick P. Successful management of kratom use disorder with buprenorphine and naloxone. Cureus. 2023;15(6):e41146. doi:10.7759/cureus.41146. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10386870/
- Management of acute withdrawal from 7-hydroxymitragynine after high-dose chronic use: a case report. American Journal of Health-System Pharmacy. 2026. https://www.sciencedirect.com/science/article/pii/S1544319126000324
- Courtney J, Kelsey G. Precipitated withdrawal with kratom use following naltrexone administration. Mental Health Clinician. 2023;13(3):155-158. doi:10.9740/mhc.2023.06.155.
- Henningfield JE, et al. Human Mitragynine and 7-Hydroxymitragynine Pharmacokinetics after Single and Multiple Daily Doses of Oral Encapsulated Dried Kratom Leaf Powder. Molecules. 2024;29(4):984. doi:10.3390/molecules29040984. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10934259/
- Substance Abuse and Mental Health Services Administration. TIP 63: Medications for Opioid Use Disorder. Publication No. PEP21-02-01-002. SAMHSA; 2021. https://library.samhsa.gov/product/tip-63-medications-opioid-use-disorder-executive-summary/pep21-02-01-003
- American Society of Addiction Medicine. The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. ASAM; 2020.
- Wightman RS, et al. A Case of 7-OH Mitragynine Use Requiring Inpatient Medically Managed Withdrawal. Journal of Addiction Medicine. Published online August 4, 2025. doi:10.1097/ADM.0000000000001558. https://pubmed.ncbi.nlm.nih.gov/40758956/
- U.S. Food and Drug Administration. FDA and Kratom. FDA; updated February 2026. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom